Eli Lilly completes acquisition of Verve Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 25 2025
0mins
Should l Buy LLY?
Eli Lilly's Acquisition: Eli Lilly and Company has successfully completed its acquisition of Verve Therapeutics, a Boston-based company focused on developing genetic medicines for cardiovascular diseases.
Focus on Cardiovascular Health: The acquisition emphasizes Eli Lilly's commitment to advancing innovative treatments in the field of cardiovascular health through genetic medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 886.630
Low
950.00
Averages
1192
High
1500
Current: 886.630
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
- Acquisition Scale: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, with an upfront payment of $38 per share representing a 38% premium over Monday's closing price, which will further solidify Lilly's leadership in the neuroscience sector.
- Drug Development Potential: The orexin agonists being developed by Centessa are expected to treat narcolepsy and other neurological conditions associated with drowsiness, with a market potential estimated between $15 billion and $20 billion, significantly enhancing Lilly's product portfolio if successfully launched.
- Market Competition Landscape: Although Centessa's drug is not expected to receive FDA approval until 2028, its competitor Taked's similar drug is under review, indicating the intense competition in the market, prompting Lilly to accelerate its development efforts to maintain its lead.
- Strategic Investment Direction: Lilly plans to leverage cash flows from its best-selling drugs Zepbound and Mounjaro for further investments, having recently announced acquisitions of cell therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences, demonstrating its commitment to expanding its product line.
See More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
- Acquisition Scale: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, with an upfront payment of $38 per share, totaling $6.3 billion, representing a 38% premium over Monday's closing price, reflecting strong confidence in the new drug development.
- Market Potential: Oppenheimer analysts estimate that the market for orexin agonists targeting excessive daytime sleepiness could reach $15 billion to $20 billion, positioning Lilly to capture significant market share if Centessa's drugs gain FDA approval.
- Optimistic R&D Outlook: Although Centessa's drug is not expected to be approved until 2028, mid-stage trial data suggests it could become the best-in-class treatment, further solidifying Lilly's leadership in neuroscience.
- Strategic Investment Direction: Lilly plans to leverage cash flow from its best-selling drugs Zepbound and Mounjaro to continue expanding its product line, having recently announced acquisitions of cell therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences, indicating a proactive approach in the biopharmaceutical sector.
See More
Buffett Teams Up with Curry for Charity Lunch Revival
- Surging Oil Prices Impact Markets: The average price of gasoline in the U.S. has surpassed $4 per gallon for the first time since 2022, leading Wall Street to face its worst monthly and quarterly losses since 2022, prompting investors to consider the potential impact of oil prices on the stock market.
- Fed's Stabilizing Signal: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, resulting in a significant drop in market expectations for future rate increases, reflecting confidence in economic stability.
- Opendoor Acquires Doma: Opendoor is acquiring parts of Doma to lower real estate transaction costs, particularly as mortgage refinancing applications decline, demonstrating the real estate market's adaptability amid rising rates due to geopolitical tensions.
- Novo Nordisk Launches Long-Term Subscriptions: Novo Nordisk has introduced multi-month subscriptions for Wegovy in an effort to compete with Eli Lilly, offering more cost-effective options that could attract additional users and enhance market share in the GLP-1 segment.
See More
Novo Nordisk Launches Wegovy Drug Subscription Program
- Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
- Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
- Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
- Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
See More
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
- Acquisition Scale: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, with an upfront payment of $38 per share representing a 38% premium over Monday's closing price, which will further solidify Lilly's leadership in the neuroscience sector.
- Drug Development Potential: The orexin agonists being developed by Centessa are expected to treat narcolepsy and other neurological conditions associated with drowsiness, with a market potential estimated between $15 billion and $20 billion, significantly enhancing Lilly's product portfolio if successfully launched.
- Market Competition Landscape: Although Centessa's drug is not expected to receive FDA approval until 2028, its competitor Taked's similar drug is under review, indicating the intense competition in the market, prompting Lilly to accelerate its development efforts to maintain its lead.
- Strategic Investment Direction: Lilly plans to leverage cash flows from its best-selling drugs Zepbound and Mounjaro for further investments, having recently announced acquisitions of cell therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences, demonstrating its commitment to expanding its product line.
See More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
- Acquisition Scale: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, with an upfront payment of $38 per share, totaling $6.3 billion, representing a 38% premium over Monday's closing price, reflecting strong confidence in the new drug development.
- Market Potential: Oppenheimer analysts estimate that the market for orexin agonists targeting excessive daytime sleepiness could reach $15 billion to $20 billion, positioning Lilly to capture significant market share if Centessa's drugs gain FDA approval.
- Optimistic R&D Outlook: Although Centessa's drug is not expected to be approved until 2028, mid-stage trial data suggests it could become the best-in-class treatment, further solidifying Lilly's leadership in neuroscience.
- Strategic Investment Direction: Lilly plans to leverage cash flow from its best-selling drugs Zepbound and Mounjaro to continue expanding its product line, having recently announced acquisitions of cell therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences, indicating a proactive approach in the biopharmaceutical sector.
See More
Buffett Teams Up with Curry for Charity Lunch Revival
- Surging Oil Prices Impact Markets: The average price of gasoline in the U.S. has surpassed $4 per gallon for the first time since 2022, leading Wall Street to face its worst monthly and quarterly losses since 2022, prompting investors to consider the potential impact of oil prices on the stock market.
- Fed's Stabilizing Signal: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, resulting in a significant drop in market expectations for future rate increases, reflecting confidence in economic stability.
- Opendoor Acquires Doma: Opendoor is acquiring parts of Doma to lower real estate transaction costs, particularly as mortgage refinancing applications decline, demonstrating the real estate market's adaptability amid rising rates due to geopolitical tensions.
- Novo Nordisk Launches Long-Term Subscriptions: Novo Nordisk has introduced multi-month subscriptions for Wegovy in an effort to compete with Eli Lilly, offering more cost-effective options that could attract additional users and enhance market share in the GLP-1 segment.
See More
Novo Nordisk Launches Wegovy Drug Subscription Program
- Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
- Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
- Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
- Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
See More
